Omnicell stock holds steady as investors await next earnings update
Published on 09/19/2026 at 20:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOmnicell stock (ISIN US6821321088) ended the last completed trading day at USD 32.62 on Nasdaq as of September 18, 2026, a gain of 0.6% compared with the prior close, according to Zacks Investment Research on September 19, 2026.
Upcoming earnings keep Omnicell stock in focus
According to Zacks Investment Research on September 19, 2026, the consensus earnings per share estimate for Omnicell's upcoming quarterly report stands at USD 0.42, unchanged over the past month.
The same Zacks overview notes that this USD 0.42 consensus figure represents a decline of 17.7% versus the EPS Omnicell reported in the comparable quarter a year earlier, highlighting that analysts expect lower profitability year on year even though earnings remain positive.
Analyst stance and fundamental expectations
Based on the current analyst view summarized by Zacks Investment Research on September 19, 2026, Omnicell carries a Zacks Rank of 3, which corresponds to a Hold rating and signals a neutral stance from the model on the near-term performance of the shares.
In the past month up to September 18, 2026, Omnicell stock has returned negative 11% according to the same Zacks data, underperforming many peers and suggesting that expectations for softer earnings have already been partially reflected in the price.
Stock performance and market metrics
On September 18, 2026, Omnicell stock closed at USD 32.62 on Nasdaq, up 0.6% in that session, while still carrying a one-month return of negative 11% as reported by Zacks Investment Research.
Omnicell stock key data
- Company: Omnicell, Inc.
- ISIN: US6821321088
- Ticker: OMCL
- Trading venue: Nasdaq
- Price (as of September 18, 2026): 32.62 USD
- Sector / Industry: Health care technology
- Index membership: None (major benchmark)
